Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 1
1994 3
1995 5
1996 2
1997 5
1998 2
2000 1
2001 2
2002 1
2003 4
2004 2
2006 2
2007 3
2008 6
2009 17
2010 16
2011 7
2012 10
2013 14
2014 16
2015 17
2016 23
2017 18
2018 10
2019 14
2020 18
2021 15
2022 19
2023 16
2024 14
2025 11

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

261 results

Results by year

Filters applied: . Clear all
Page 1
Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.
Leon-Ferre RA, Jonas SF, Salgado R, Loi S, de Jong V, Carter JM, Nielsen TO, Leung S, Riaz N, Chia S, Jules-Clément G, Curigliano G, Criscitiello C, Cockenpot V, Lambertini M, Suman VJ, Linderholm B, Martens JWM, van Deurzen CHM, Timmermans AM, Shimoi T, Yazaki S, Yoshida M, Kim SB, Lee HJ, Dieci MV, Bataillon G, Vincent-Salomon A, André F, Kok M, Linn SC, Goetz MP, Michiels S; International Immuno-Oncology Biomarker Working Group. Leon-Ferre RA, et al. Among authors: linn sc. JAMA. 2024 Apr 2;331(13):1135-1144. doi: 10.1001/jama.2024.3056. JAMA. 2024. PMID: 38563834 Free PMC article.
Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
van Ramshorst MS, van der Voort A, van Werkhoven ED, Mandjes IA, Kemper I, Dezentjé VO, Oving IM, Honkoop AH, Tick LW, van de Wouw AJ, Mandigers CM, van Warmerdam LJ, Wesseling J, Vrancken Peeters MT, Linn SC, Sonke GS; Dutch Breast Cancer Research Group (BOOG). van Ramshorst MS, et al. Among authors: linn sc. Lancet Oncol. 2018 Dec;19(12):1630-1640. doi: 10.1016/S1470-2045(18)30570-9. Epub 2018 Nov 6. Lancet Oncol. 2018. PMID: 30413379 Clinical Trial.
Taxanes trigger cancer cell killing in vivo by inducing non-canonical T cell cytotoxicity.
Vennin C, Cattaneo CM, Bosch L, Vegna S, Ma X, Damstra HGJ, Martinovic M, Tsouri E, Ilic M, Azarang L, van Weering JRT, Pulver E, Zeeman AL, Schelfhorst T, Lohuis JO, Rios AC, Dekkers JF, Akkari L, Menezes R, Medema R, Baglio SR, Akhmanova A, Linn SC, Lemeer S, Pegtel DM, Voest EE, van Rheenen J. Vennin C, et al. Among authors: linn sc. Cancer Cell. 2023 Jun 12;41(6):1170-1185.e12. doi: 10.1016/j.ccell.2023.05.009. Cancer Cell. 2023. PMID: 37311414 Free article.
Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual ERBB2 Blockade in Patients With ERBB2-Positive Breast Cancer: A Secondary Analysis of the TRAIN-2 Randomized, Phase 3 Trial.
van der Voort A, van Ramshorst MS, van Werkhoven ED, Mandjes IA, Kemper I, Vulink AJ, Oving IM, Honkoop AH, Tick LW, van de Wouw AJ, Mandigers CM, van Warmerdam LJ, Wesseling J, Vrancken Peeters MT, Linn SC, Sonke GS. van der Voort A, et al. Among authors: linn sc. JAMA Oncol. 2021 Jul 1;7(7):978-984. doi: 10.1001/jamaoncol.2021.1371. JAMA Oncol. 2021. PMID: 34014249 Free PMC article. Clinical Trial.
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.
Voorwerk L, Slagter M, Horlings HM, Sikorska K, van de Vijver KK, de Maaker M, Nederlof I, Kluin RJC, Warren S, Ong S, Wiersma TG, Russell NS, Lalezari F, Schouten PC, Bakker NAM, Ketelaars SLC, Peters D, Lange CAH, van Werkhoven E, van Tinteren H, Mandjes IAM, Kemper I, Onderwater S, Chalabi M, Wilgenhof S, Haanen JBAG, Salgado R, de Visser KE, Sonke GS, Wessels LFA, Linn SC, Schumacher TN, Blank CU, Kok M. Voorwerk L, et al. Among authors: linn sc. Nat Med. 2019 Jun;25(6):920-928. doi: 10.1038/s41591-019-0432-4. Epub 2019 May 13. Nat Med. 2019. PMID: 31086347 Clinical Trial.
Predictive gene expression profile for adjuvant taxane benefit in breast cancer in the MATADOR trial.
Opdam M, van Rossum AGJ, Hoogstraat M, Bounova G, Horlings HM, van Werkhoven E, Mandjes IAM, van Leeuwen-Stok AE, Canisius S, van Tinteren H, Imholz ALT, Portielje JEA, Bos MEMM, Bakker S, Wesseling J, Kester L, van Rheenen J, Rutgers EJ, de Menezes RX, Wessels LFA, Kok M, Oosterkamp HM, Linn SC; MATADOR trialists’ group for the Dutch Breast Cancer Research Group (BOOG). Opdam M, et al. Among authors: linn sc. iScience. 2024 Jun 29;27(8):110425. doi: 10.1016/j.isci.2024.110425. eCollection 2024 Aug 16. iScience. 2024. PMID: 39206149 Free PMC article.
De-escalation of radiotherapy after primary chemotherapy in cT1-2N1 breast cancer (RAPCHEM; BOOG 2010-03): 5-year follow-up results of a Dutch, prospective, registry study.
de Wild SR, de Munck L, Simons JM, Verloop J, van Dalen T, Elkhuizen PHM, Houben RMA, van Leeuwen AE, Linn SC, Pijnappel RM, Poortmans PMP, Strobbe LJA, Wesseling J, Voogd AC, Boersma LJ. de Wild SR, et al. Among authors: linn sc. Lancet Oncol. 2022 Sep;23(9):1201-1210. doi: 10.1016/S1470-2045(22)00482-X. Epub 2022 Aug 8. Lancet Oncol. 2022. PMID: 35952707
Tumor-Infiltrating Lymphocytes in Patients With Stage I Triple-Negative Breast Cancer Untreated With Chemotherapy.
Geurts VCM, Balduzzi S, Steenbruggen TG, Linn SC, Siesling S, Badve SS, DeMichele A, Ignatiadis M, Leon-Ferre RA, Goetz MP, Wolff AC, Klar N, Michiels S, Loi S, Adams S, Horlings HM, Sonke GS, Salgado R, Kok M. Geurts VCM, et al. Among authors: linn sc. JAMA Oncol. 2024 Aug 1;10(8):1077-1086. doi: 10.1001/jamaoncol.2024.1917. JAMA Oncol. 2024. PMID: 38935352 Free PMC article.
Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial.
Nederlof I, Isaeva OI, de Graaf M, Gielen RCAM, Bakker NAM, Rolfes AL, Garner H, Boeckx B, Traets JJH, Mandjes IAM, de Maaker M, van Brussel T, Chelushkin M, Champanhet E, Lopez-Yurda M, van de Vijver K, van den Berg JG, Hofland I, Klioueva N, Mann RM, Loo CE, van Duijnhoven FH, Skinner V, Luykx S, Kerver E, Kalashnikova E, van Dongen MGJ, Sonke GS, Linn SC, Blank CU, de Visser KE, Salgado R, Wessels LFA, Drukker CA, Schumacher TN, Horlings HM, Lambrechts D, Kok M. Nederlof I, et al. Among authors: linn sc. Nat Med. 2024 Nov;30(11):3223-3235. doi: 10.1038/s41591-024-03249-3. Epub 2024 Sep 16. Nat Med. 2024. PMID: 39284953 Free PMC article. Clinical Trial.
Fertility preservation for women with breast cancer: a multicentre randomized controlled trial on various ovarian stimulation protocols.
Balkenende EME, Dahhan T, Beerendonk CCM, Fleischer K, Stoop D, Bos AME, Lambalk CB, Schats R, Smeenk JMJ, Louwé LA, Cantineau AEP, de Bruin JP, Linn SC, van der Veen F, van Wely M, Goddijn M. Balkenende EME, et al. Among authors: linn sc. Hum Reprod. 2022 Jul 30;37(8):1786-1794. doi: 10.1093/humrep/deac145. Hum Reprod. 2022. PMID: 35776109 Free PMC article. Clinical Trial.
261 results